657 related articles for article (PubMed ID: 33161769)
41. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
43. Statin safety: a systematic review.
Law M; Rudnicka AR
Am J Cardiol; 2006 Apr; 97(8A):52C-60C. PubMed ID: 16581329
[TBL] [Abstract][Full Text] [Related]
44. Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
Wei C; Yin W; He Z; Wu B
J Clin Med; 2023 May; 12(10):. PubMed ID: 37240654
[TBL] [Abstract][Full Text] [Related]
45. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
46. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Chang JT; Staffa JA; Parks M; Green L
Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
[TBL] [Abstract][Full Text] [Related]
47. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
[TBL] [Abstract][Full Text] [Related]
48. Safety of High-Intensity Statins in the Veteran Population: Atorvastatin 40 to 80 mg Compared With Rosuvastatin 20 to 40 mg.
Stein B; Ward T; Hale G; Lyver E
Ann Pharmacother; 2020 May; 54(5):405-413. PubMed ID: 31718234
[No Abstract] [Full Text] [Related]
49. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
Jones PH; Davidson MH
Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
[TBL] [Abstract][Full Text] [Related]
50. Interaction potential between clarithromycin and individual statins-A systematic review.
Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
[TBL] [Abstract][Full Text] [Related]
51. Meta-analysis of the Placebo and Nocebo effects associated with Placebo treatment in randomized trials of lipid-lowering therapies.
Chin YH; Lim O; Lin C; Chan YY; Kong G; Ng CH; Chong B; Syn N; Chan KE; Muthiah MD; Siddiqui MS; Wang JW; Figtree G; Chan MY; Chew NWS
Eur Heart J Qual Care Clin Outcomes; 2023 Aug; 9(5):511-519. PubMed ID: 36107462
[TBL] [Abstract][Full Text] [Related]
52. Physicians' Experiences as Patients with Statin Side Effects: A Case Series.
Koslik HJ; Meskimen AH; Golomb BA
Drug Saf Case Rep; 2017 Dec; 4(1):3. PubMed ID: 28217821
[TBL] [Abstract][Full Text] [Related]
53. Muscle and statins: from toxicity to the nocebo effect.
Pedro-Botet J; Climent E; Benaiges D
Expert Opin Drug Saf; 2019 Jul; 18(7):573-579. PubMed ID: 31070941
[TBL] [Abstract][Full Text] [Related]
54. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.
Golomb BA; Evans MA
Am J Cardiovasc Drugs; 2008; 8(6):373-418. PubMed ID: 19159124
[TBL] [Abstract][Full Text] [Related]
55. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
56. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
[TBL] [Abstract][Full Text] [Related]
57. Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review.
Häuser W; Bartram C; Bartram-Wunn E; Tölle T
Clin J Pain; 2012 Jun; 28(5):437-51. PubMed ID: 22336767
[TBL] [Abstract][Full Text] [Related]
58. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
59. Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.
Takada M; Fujimoto M; Yamazaki K; Takamoto M; Hosomi K
Drug Saf; 2014 Jun; 37(6):421-31. PubMed ID: 24743876
[TBL] [Abstract][Full Text] [Related]
60. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Strutt K; Caplan R; Hutchison H; Dane A; Blasetto J
Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
